Albireo Announces Positive Clinical Data On A3309 In Patients With Chronic Idiopathic Constipation

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
18th November 2009, 10:20pm - Views: 677





Community Health Albireo 1 image

Community Health Albireo 2 image









MEDIA RELEASE PR37140


Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation


GOTHENBURG, Nov. 18 /PRNewswire-AsiaNet/ --


    Albireo today announced the completion of a phase 1b study showing a 

favourable tolerability and safety profile of A3309 in patients with chronic 

idiopathic constipation. In addition, the data revealed appropriate efficacy 

signals in this patient population. A3309 is a first in class compound 

developed for the treatment of chronic idiopathic constipation and 

constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these 

results, Albireo expects to recruit 180 patients with chronic idiopathic 


IND recently placed into effect by the FDA.


    Notes for Editors:


    About CIC


    Constipation is one of the most common gastrointestinal complaints.

Chronic idiopathic constipation is a more severe and disabling disease, which

is not effectively managed by current treatment options. More than 4 million

Americans have chronic constipation resulting in 9 million physician visits

annually and in addition lead to more than 92,000 hospitalizations annually.

In a survey study of 557 individuals with chronic constipation, 47% of

respondents indicated a lack of satisfaction with treatment (82% citing lack

of treatment efficacy as the reason for dissatisfaction).


    About A3309


    A3309 is a therapeutic alternative with a novel mechanism of action

developed for the treatment of chronic idiopathic constipation and

constipation-predominant Irritable Bowel Syndrome (IBS-C). A3309 modulates

the re-uptake of bile acids by inhibiting the ileal bile acid transporter.

This will result in an increased concentration of bile acids in the colon

which, in turn, increase fluid secretion and colonic motility. These

physiological responses should provide benefits to patients with chronic

constipation and IBS-C without any effects on other parts of the

gastrointestinal tract.


    About Albireo


    Albireo is an independent Swedish biotechnology company focused on the

development of novel therapeutic alternatives to fulfill medical needs in the

gastrointestinal area. Albireo was spun-out of AstraZeneca in February 2008

and is financed by a syndicate of growth capital firms, including Nomura

Phase4 Ventures, TPG growth, TVM Capital and Scottish Widows Investment

Partnership. The company has raised $40m in its Series A financing round


    

    SOURCE: Albireo


Translations:


To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article